Lyell Immunopharma (LYEL)
NASDAQ:LYEL
LYEL Stock Chart & Stats
$21.78
-$0.01(-1.66%)
At close: 4:00 PM EST
$21.78
-$0.01(-1.66%)
Day’s Range― - ―
52-Week Range$7.65 - $45.00
Previous CloseN/A
Volume124.06K
Average Volume (3M)101.82K
Market Cap
$507.63M
Enterprise Value$489.37M
Total Cash (Recent Filing)$247.22M
Total Debt (Recent Filing)$41.92M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
May 12, 2026EPS Estimate
-2.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.18
Shares Outstanding23,307,142
10 Day Avg. Volume80,410
30 Day Avg. Volume101,816
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.12
Price to Sales (P/S)14614.51
P/FCF Ratio-3.49
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue13.59K
Enterprise Value/Gross Profit-207.27
Enterprise Value/Ebitda-2.55
Forecast
1Y Price Target
$39.50Price Target Upside81.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-9.33
Revenue Forecast (FY)$18.00K
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationA randomized head-to-head Phase 3 trial versus approved CAR-T therapies could demonstrate superior response and durability, strengthening Lyell's clinical differentiation versus competitors.
Financial And Operational ResilienceA strong cash position with no debt and available in-house manufacturing capacity supports funding of key clinical readouts and preparations for potential commercialization.
New Indication OpportunityLYL273's encouraging activity in metastatic colorectal cancer that exceeds standard-of-care response levels could create a second major commercial opportunity beyond lymphoma.
Bears Say
Efficacy RiskReduced efficacy in pivotal trials would limit real-world uptake and undermine the projected market potential in both lymphoma and colorectal indications.
Market Access And AdoptionAltered risk-benefit assessments could hinder payer coverage and physician willingness to adopt the therapies even if primary endpoints are achieved.
Safety ConcernsAn unexpected safety issue with a lead asset could alter the therapies' risk-benefit profiles and constrain regulatory approvals and clinician adoption.
Lyell Immunopharma News
LYEL FAQ
What was Lyell Immunopharma’s price range in the past 12 months?
Lyell Immunopharma lowest stock price was $7.65 and its highest was $45.00 in the past 12 months.
What is Lyell Immunopharma’s market cap?
Lyell Immunopharma’s market cap is $507.63M.
When is Lyell Immunopharma’s upcoming earnings report date?
Lyell Immunopharma’s upcoming earnings report date is May 12, 2026 which is in 34 days.
How were Lyell Immunopharma’s earnings last quarter?
Lyell Immunopharma released its earnings results on Mar 12, 2026. The company reported -$7.18 earnings per share for the quarter, missing the consensus estimate of -$2.232 by -$4.948.
Is Lyell Immunopharma overvalued?
According to Wall Street analysts Lyell Immunopharma’s price is currently Undervalued.
Does Lyell Immunopharma pay dividends?
Lyell Immunopharma does not currently pay dividends.
What is Lyell Immunopharma’s EPS estimate?
Lyell Immunopharma’s EPS estimate is -2.31.
How many shares outstanding does Lyell Immunopharma have?
Lyell Immunopharma has 23,307,142 shares outstanding.
What happened to Lyell Immunopharma’s price movement after its last earnings report?
Lyell Immunopharma reported an EPS of -$7.18 in its last earnings report, missing expectations of -$2.232. Following the earnings report the stock price went down -14.228%.
Which hedge fund is a major shareholder of Lyell Immunopharma?
Currently, no hedge funds are holding shares in LYEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lyell Immunopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.50 (81.36% Upside)
$39.50 (81.36% Upside)
Blogger Sentiment
Bullish
LYEL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 98.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $24.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
133.32%
12-Months-Change
Fundamentals
Return on Equity
-90.52%
Trailing 12-Months
Asset Growth
-30.72%
Trailing 12-Months
Company Description
Lyell Immunopharma
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
LYEL Stock 12 Month Forecast
Average Price Target
$39.50
▲(81.36% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Editas Medicine
―
Mereo Biopharma Group Plc
―
Replimune Group
―
―
Ownership Overview
47.41% Insiders
7.06% Mutual Funds
33.16% Other Institutional Investors
8.25% Public Companies and
Individual Investors